Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Contraceptives, Oral Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Efficacy and Body Weight

NCT00662454
View directory record Official record
Conditions
Contraception, Body Weight
Interventions
ethinyl estradiol / levonorgestrel
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Oral Androgens in Man-4: (Short Title: Oral T-4)

NCT00399165
View directory record Official record
Conditions
Contraception
Interventions
Testosterone Enanthate, Dutasteride, placebo sesame oil
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2008 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

NCT00394771
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
DR-1031, Seasonale®, Portia®
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
567 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Jul 22, 2026, 11:35 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

NCT00901290
View directory record Official record
Conditions
Pharmacokinetics
Interventions
monophasic oral contraceptive, AZD7325
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2010 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

NCT03324685
View directory record Official record
Conditions
Drug Interactions
Interventions
BIIB074, OC (ethinyl estradiol and levonorgestrel)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Contraceptives on Cervico-Vaginal Mucosa

NCT04814927
View directory record Official record
Conditions
Mucosal Inflammation, Contraceptive; Complications, Intrauterine
Interventions
Copper IUD, Etonogestrel implant, Levonorgestrel IUS, DMPA Sub-cutaneous
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne

NCT00656981
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
22
States / cities
Mobile, Alabama • Kingman, Arizona • Encino, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prune Consumption and Bone Health in Young Women Using Hormonal Contraceptives

NCT04785131
View directory record Official record
Conditions
Osteoporosis Risk
Interventions
Prune
Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

NCT00640224
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
rosiglitazone, drospirenone/ethinyl estradiol
Drug
Lead sponsor
Silva Arslanian
Other
Eligibility
10 Years to 20 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects

NCT00821496
View directory record Official record
Conditions
Healthy
Interventions
ethinyl estradiol, norethindrone, VI-0521
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 64 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Ovulation Incidence in Oral Contraceptive Users

NCT03106454
View directory record Official record
Conditions
Contraception, Ovulation
Interventions
Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 22, 2026, 11:35 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

NCT07502417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ethinyl Estradiol + Levonorgestrel, ABBV-722
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 11:35 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Direct Access Study: Access to Hormonal Birth Control Through Community Pharmacies

NCT00065871
View directory record Official record
Conditions
Contraception
Interventions
Contraceptive Screening by Pharmacist, Contraceptive Prescribing by Pharmacist
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
5
States / cities
Kent, Washington • Kirkland, Washington • Puyallup-South Hill, Washington + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2007 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers

NCT00504816
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075, Brevicon
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

NCT00754065
View directory record Official record
Conditions
Contraception
Interventions
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ortho Tri Cyclen Lo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
34
States / cities
Independence, Arizona • Phoenix, Arizona • Encinitas, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Adolescent Adherence to Hormonal Contraception

NCT00584038
View directory record Official record
Conditions
Contraception
Interventions
educational instruction and phone follow-up, educational instruction in clinic
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
1,155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Jul 22, 2026, 11:35 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

NCT01963403
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Interventions
EE 30mcg/LNG 150mcg, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
14 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Sacramento, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

NCT05461573
View directory record Official record
Conditions
Contraception, Change in Bone Mineral Density
Interventions
Drospirenone
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
13 Years to 45 Years · Female only
Enrollment
1,542 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
46
States / cities
Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

NCT06250205
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC)
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

NCT00781456
View directory record Official record
Conditions
Migraine
Interventions
91-day Levonorgestrel Oral Contraceptive, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
La Mesa, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Jul 22, 2026, 11:35 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

NCT07013643
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 11:35 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales

NCT02210702
View directory record Official record
Conditions
Postpartum Depressive Mood, Postpartum Sexual Function
Interventions
Ethinyl Estradiol 35mcg/Norethindrone 1mg, Ethinyl Estradiol 20mcg/Norethindrone 1mg
Drug
Lead sponsor
The Jones Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Jul 22, 2026, 11:35 AM EDT